High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

被引：13
|
作者：
Huang, Wenrong [1 ]
Li, Jian [2 ]
Li, Honghua [1 ]
Kang, Wenying [2 ]
Bo, Jian [1 ]
Zhao, Yu [1 ]
Gao, Chunji [1 ]
Zhou, Daobin [2 ]
Yu, Li [1 ]
机构：
[1] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China
[2] Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 12期
关键词：
INTERGROUPE FRANCOPHONE; DEXAMETHASONE; VINCRISTINE; PREDNISONE; PHASE-2; TRIAL;
D O I：
10.3109/10428194.2012.685735
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2507 / 2510
页数：4
相关论文
共 50 条
  • [1] Comparison of high-dose melphalan with or without bortezomib as conditioning regimen for autologous stem cell transplantation in newly diagnosed multiple myeloma patients beyond very good partial response after bortezomib-based induction therapy
    Huang, W.
    Li, J.
    Li, H.
    Kang, W.
    Bo, J.
    Zhao, Y.
    Gao, C.
    Zhou, D.
    Yu, L.
    Huang, W.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S331 - S331
  • [2] Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma
    Blanes, Margarita
    Gonzalez, Jose D.
    Lahuerta, Juan J.
    Ribas, Paz
    Lorenzo, Ignacio
    Boluda, Blanca
    Sanz, Miguel A.
    de la Rubia, Javier
    LEUKEMIA & LYMPHOMA, 2015, 56 (02) : 415 - 419
  • [3] Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients
    Dalla Palma, Benedetta
    Prezioso, Lucia
    Accardi, Fabrizio
    Bisbano, Stefano
    De Luca, Federica
    Aversa, Franco
    Giuliani, Nicola
    BLOOD, 2016, 128 (22)
  • [4] Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Rodriguez, Tulio E.
    Hari, Parameswaran
    Stiff, Patrick J.
    Smith, Scott E.
    Sterrenberg, Danielle
    Vesole, David H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (08) : 1391 - 1396
  • [5] BORTEZOMIB WITH HIGH DOSE MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND IMPROVES THE RESPONSE RATE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dalla Palma, B.
    Prezioso, L.
    Accardi, F.
    Rossetti, E.
    Aversa, F.
    Giuliani, N.
    HAEMATOLOGICA, 2015, 100 : 160 - 160
  • [6] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kamimura, Tomohiko
    Muta, Tsuyoshi
    Takashima, Shuichiro
    Ito, Yoshikiyo
    Shiratsuchi, Motoaki
    Choi, Ilseung
    Kato, Koji
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Takamatsu, Yasushi
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (03) : 337 - 345
  • [7] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Toshihiro Miyamoto
    Goichi Yoshimoto
    Tomohiko Kamimura
    Tsuyoshi Muta
    Shuichiro Takashima
    Yoshikiyo Ito
    Motoaki Shiratsuchi
    Ilseung Choi
    Koji Kato
    Katsuto Takenaka
    Hiromi Iwasaki
    Yasushi Takamatsu
    Takanori Teshima
    Koichi Akashi
    International Journal of Hematology, 2013, 98 : 337 - 345
  • [8] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
  • [9] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
  • [10] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    Dunia, D. M.
    Dolores, M.
    Dolores, S.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Alejandro, V.
    Sonia, H.
    Blanca, P.
    HAEMATOLOGICA, 2016, 101 : 862 - 862
12345